Publications en collaboration avec des chercheurs de Heidelberg University (12)

2023

  1. Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT

    Bone Marrow Transplantation, Vol. 58, Núm. 11, pp. 1182-1188

  2. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

    Nature Communications, Vol. 14, Núm. 1

2019

  1. Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016

    British Journal of Haematology

2018

  1. Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network

    Leukemia, Vol. 32, Núm. 7, pp. 1542-1560

2017

  1. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Annals of Oncology, Vol. 28, pp. iv52-iv61

2016

  1. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

  2. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

    The Lancet Oncology, Vol. 17, Núm. 8, pp. e328-e346

  3. Multiple myeloma: practice patterns across Europe

    British Journal of Haematology, Vol. 175, Núm. 1, pp. 66-76

  4. Treatment of multiple myeloma with high-risk cytogenetics: A consensus of the International Myeloma Working Group

    Blood, Vol. 127, Núm. 24, pp. 2955-2962

2015

  1. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma

    Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 12, pp. 2039-2051

2014

  1. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

    The Lancet Oncology, Vol. 15, Núm. 12, pp. e538-e548

2011

  1. Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. Melphalan-prednisone in the phase III VISTA trial in multiple myeloma

    European Journal of Haematology, Vol. 86, Núm. 5, pp. 372-384